Literature DB >> 21611957

Evaluating markers for treatment selection based on survival time.

Xiao Song1, Xiao-Hua Zhou.   

Abstract

For many medical conditions, several treatment options may be available for treating patients. We consider evaluating markers based on a simple treatment selection policy that incorporates information on the patient's marker value. For example, colon cancer patients may be treated by surgery alone or surgery plus chemotherapy. The c-myc gene expression level may be used as a biomarker for treatment selection. Although traditional regression methods may assess the effect of the marker and treatment on outcomes, it is more appealing to quantify directly the potential impact on the population of using the marker to select treatment. A useful tool is the selection impact (SI) curve proposed by Song and Pepe for binary outcomes (Biometrics 2004; 60:874-883). However, the current SI method does not deal with continuous outcomes, nor does it allow to adjust for other covariates that are important for treatment selection. In this paper, we extend the SI curve for general outcomes, with a specific focus on survival time. We further propose the covariate-specific SI curve to incorporate covariate information in treatment selection. Nonparametric and semiparametric estimators are developed accordingly. We show that the proposed estimators are consistent and asymptotically normal. The performance is assessed by simulation studies and illustrated through an application to data from a cancer clinical trial.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21611957     DOI: 10.1002/sim.4258

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  Estimation of treatment policies based on functional predictors.

Authors:  Ian W McKeague; Min Qian
Journal:  Stat Sin       Date:  2014-07       Impact factor: 1.261

2.  Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer.

Authors:  Holly Janes; Marshall D Brown; Michael R Crager; Dave P Miller; William E Barlow
Journal:  Contemp Clin Trials       Date:  2017-08-14       Impact factor: 2.226

Review 3.  Incorporation of prognostic and predictive factors into glioma clinical trials.

Authors:  Derek R Johnson; Evanthia Galanis
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

4.  Evaluating biomarkers for treatment selection from reproducibility studies.

Authors:  Xiao Song; Kevin K Dobbin
Journal:  Biostatistics       Date:  2022-01-13       Impact factor: 5.899

5.  Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data.

Authors:  Francesca Bovis; Luca Carmisciano; Alessio Signori; Matteo Pardini; Joshua R Steinerman; Thomas Li; Aaron P Tansy; Maria Pia Sormani
Journal:  BMC Med       Date:  2019-06-18       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.